Technical Analysis for ZURA - Zura Bio Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 4.71 | 1.51% | 0.07 |
ZURA closed up 1.51 percent on Wednesday, May 8, 2024, on 27 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
NR7 | Range Contraction | 1.51% | |
Stochastic Reached Overbought | Strength | 1.51% | |
Wide Bands | Range Expansion | 1.51% | |
Overbought Stochastic | Strength | 1.51% | |
200 DMA Resistance | Bearish | 0.43% | |
Wide Bands | Range Expansion | 0.43% | |
Up 3 Days in a Row | Strength | 0.43% |
Alert | Time |
---|---|
200 DMA Resistance | about 18 hours ago |
60 Minute Opening Range Breakout | about 19 hours ago |
Rose Above Previous Day's High | about 19 hours ago |
Rose Above 200 DMA | about 19 hours ago |
Up 3% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.0 |
52 Week Low | 2.0 |
Average Volume | 346,751 |
200-Day Moving Average | 4.75 |
50-Day Moving Average | 3.34 |
20-Day Moving Average | 3.84 |
10-Day Moving Average | 4.41 |
Average True Range | 0.42 |
RSI (14) | 67.32 |
ADX | 38.51 |
+DI | 33.55 |
-DI | 10.27 |
Chandelier Exit (Long, 3 ATRs) | 3.68 |
Chandelier Exit (Short, 3 ATRs) | 3.97 |
Upper Bollinger Bands | 5.11 |
Lower Bollinger Band | 2.57 |
Percent B (%b) | 0.84 |
BandWidth | 66.30 |
MACD Line | 0.42 |
MACD Signal Line | 0.33 |
MACD Histogram | 0.0972 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.18 | ||||
Resistance 3 (R3) | 5.18 | 5.02 | 5.10 | ||
Resistance 2 (R2) | 5.02 | 4.90 | 5.02 | 5.07 | |
Resistance 1 (R1) | 4.87 | 4.83 | 4.95 | 4.87 | 5.05 |
Pivot Point | 4.71 | 4.71 | 4.75 | 4.71 | 4.71 |
Support 1 (S1) | 4.56 | 4.59 | 4.64 | 4.56 | 4.37 |
Support 2 (S2) | 4.40 | 4.52 | 4.40 | 4.35 | |
Support 3 (S3) | 4.25 | 4.40 | 4.32 | ||
Support 4 (S4) | 4.25 |